A Study on the Effect of Chemotherapy Combined With Anti-HIV Drugs in HIV-Positive Patients
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring Cyclophosphamide, Dose-Response Relationship, Drug, Drug Therapy, Combination, Granulocyte Colony-Stimulating Factor, Combined Modality Therapy, Antineoplastic Agents, Lymph Nodes, Stavudine, HIV Protease Inhibitors, Lamivudine, DNA, Viral, RNA, Viral, Reverse Transcriptase Inhibitors, Anti-HIV Agents, Nelfinavir, Antineoplastic Agents, Alkylating
Eligibility Criteria
Inclusion Criteria You may be eligible for this study if you: Are HIV-positive. Have a CD4 count above 300 cells/mm3 within 30 days of study entry. Have an HIV viral load between 10,000 and 200,000 copies/ml. Are between the ages of 18 and 50. Agree to practice abstinence or to use a barrier method of birth control during the study (such as condoms). Exclusion Criteria You may not be eligible for this study if you: Have had cancer requiring chemotherapy or radiotherapy or certain nervous system diseases. Are sensitive to E. coli-derived proteins. Have an active AIDS-defining illness. Require certain medications. Are pregnant or breast-feeding.
Sites / Locations
- Univ of North Carolina
- Duke Univ Med Ctr